Ligand binding and co-activator assembly of the peroxisome proliferator- activated receptor-γ

Nature

Volumn 395, Issue 6698, 1998, Pages 137-143

  Nolte, Robert T ^a   Wisely, G Bruce ^a   Westin, Stefan ^b   Cobb, Jeffery E ^a   Lambert, Millard H ^a   Kurokawa, Riki ^b   Rosenfeld, Michael G ^c   Willson, Timothy M ^a   Glass, Christopher K ^b   Milburn, Michael V ^a  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ADIPOCYTE; ARTICLE; CELL DIFFERENTIATION; CRYSTAL STRUCTURE; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR INTERACTION; PEROXISOME; PRIORITY JOURNAL; PROTEIN ASSEMBLY; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; BINDING SITES; CLONING, MOLECULAR; CONSERVED SEQUENCE; CRYSTALLOGRAPHY, X-RAY; ESCHERICHIA COLI; HISTONE ACETYLTRANSFERASES; HUMANS; HYPOGLYCEMIC AGENTS; LIGANDS; MACROMOLECULAR SUBSTANCES; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; THIAZOLIDINEDIONES; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS;

EID: 0032505096     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/25931     Document Type: Article

References (48)

1. Mangelsdorf, D. J. et al. The nuclear receptor superfamily: the second decade. Cell 83, 835-839 (1995).
2. Kliewer, S. A. et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptor α and γ. Proc. Natl Acad. Sci. USA 94, 4318-4323 (1997).
3. Forman, B. M., Chen, J. & Evans, R. M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome profilerator-activated receptor α and δ. Proc. Natl Acad. Sci. USA 94, 4312-4317 (1997).
4. Kliewer, S. A. et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl Acad. Sci. USA 91, 7355-7359 (1994).
5. Chawla, A., Schwartz, E. J., Dimaculangan, D. D. & Lazar, M. A. Peroxisome proliferator-activated receptor γ: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinol. 135, 798-800 (1994).
6. Willson, T. M. et al. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. 39, 665-668 (1996).
7. Wu, Z., Bucher, N. L. R. & Farmer, S. R. Induction of peroxisome proliferator-activated receptor γ during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPβ, C/EBPδ, and glucocorticoids. Mol. Cell. Biol. 16, 4128-4136 (1996).
8. Tontonoz, P., Hu, E., Graves, R., Budavari, A. & Spiegelman, B. mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8, 1224-1234 (1994).
9. Tontonoz, P., Hu, E., & Spiegelman, B. M. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid activated transcription factor. Cell 79, 1147-1156 (1994).
10. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J. & Glass, C. K. The peroxisome proliferator-activated receptor γ is a negative regulator of macrophage activation. Nature 391, 79-82 (1998).
11. Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A. & Evans, R. M. PPARγ promotes monocyte/ macrophage differentiation and uptake of oxidized LDL. Cell 93, 241-252 (1998).
12. Brun, R. P. et al. Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev. 10, 974-984 (1996).
13. Lehmann, J. M. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270, 12953-12956 (1995).
14. Hulin, B., McCarthy, P. A. & Gibbs, E. M. The glitazone family of antidiabetic agents. Curr. Pharm. Des. 2, 85-102 (1996).
15. Evans, R. M. The steroid and thyroid hormone receptor superfamily. Science 240, 889-895 (1988).
16. Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H. & Moras, D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α. Nature 375, 377-382 (1995).
17. Wagner, R. L. et al. A structural role for hormone in the thyroid hormone receptor. Nature 378, 690-697 (1995).
18. Renaud, J.-P. et al. Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature 378, 681-689 (1995).
19. Brzozowski, A. M. et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753-758 (1997).
20. Horwitz, K. B. et al. Nuclear receptor coactivators and corepressors. Mol. Endocrinol. 10, 1167-1177 (1996).
21. Glass, C. K., Rose, D. W. & Rosenfeld, M. G. Nuclear receptor coactivators. Curr. Opin. Cell Biol. 9, 222-232 (1997).
22. Barettino, D., Vivanco Ruìz, M. M. & Stunnenberg, H. G. Characterization of the ligand-dependent transactivation domain of thyroid hormone receptor. EMBO J. 13, 3039-3049 (1994).
23. Danielian, P. S., White, R., Lees, J. A. & Parker, M. G. Identification of a conserved region required for hormone-dependent transcriptional activation by steroid hormone receptors. EMBO J. 11, 1025-1033 (1992).
24. Durand, B. et al. Activation function 2 (AF-2) of retinoic acid receptor and 9-cis retinoic acid receptor; presence of a conserved autonomous constitutive activating domain and influence of the nature of the response element on AF-2 activity. EMBO J. 13, 5370-5382 (1994).
25. Tone, Y., Collingwood, T. N., Adams, M. & Chatterjee, V. K. Functional analysis of a transactivation domain in the thyroid hormone beta receptor. J. Biol. Chem. 269, 31157-31161 (1994).
26. Voegel, J. J., Heine, M. J. S., Zechel, C., Chambon, P. & Gronemeyer, H. TIF2, a 160 kD a transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 15, 3667-3675 (1996).
27. Torchia, J. et al. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387, 677-684 (1997).
28. Zhu, Y., Qi, C., Calandra, C., Rao, M. S. & Reddy, J. K. Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor γ. Gene Expr. 6, 185-195 (1996).
29. Hong, H., Kohli, K., Garabedian, M. J. & Stallcup, M. R. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol. Cell. Biol. 17, 2735-2744 (1997).
30. Anzick, S. L. et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277, 965-968 (1997).
31. Chen, H. et al. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90, 569-580 (1997).
32. Kamei, Y. et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85, 403-414 (1996).
33. Voegel, J. J. et al. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J. 17, 507-519 (1998).
34. Heery, D. M., Kalkhoven, E., Hoare, S. & Parker, M. G. A signature motif in transcriptional coactivators mediates binding to nuclear receptors. Nature 387, 733-736 (1997).
35. Keen, H. Insulin resistance and the prevention of diabetes mellitus. New. Eng. J. Med. 331, 1226-1227 (1994).
36. Buckle, D. R. et al. Non-thazolidinedione antihyperglycemic agents. 2: α-Carbon substituted β-phenylpropanoic acids. Bioorg. Med. Chem. Lett. 6, 2127-2130 (1996).
37. Westin, S. et al. Interactions controlling complexes of nuclear-receptor heterodimers and coactivators. Nature 395, 199-202 (1998).
38. Feng, X. et al. Suprabasal expression of a dominant-negative RXR alpha mutant in transgenic mouse epidermis impairs regulation of gene transcription and basal keratinocyte proliferation by RAR-selective retinoids. Genes Dev. 11, 59-71 (1997).
39. Durand, B. et al. Activation function 2 (AF-2) of retinoic acid receptor and 9-cis retinoic acid receptor: presence of a conserved autonomous constitutive activating domain and influence of the nature of the response element on AF-2 activity. EMBO J. 13, 5370-5382 (1994).
40. Henttu, P. M. A., Kalkhoven, E. & Parker, M. G. AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors. Mol. Cell. Biol. 17, 1832-1839 (1997).
41. Kurokawa, R. et al. Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding. Nature 371, 528-531 (1994).
42. Forman, B. M., Umesono, K., Chen, J. & Evans, R. M. Unique response pathways are established by allosteric interactions among nuclear hormone receptors. Cell 81, 541-550 (1995).
43. Otwinowski, Z., Isaacs, N. & Burley, S. in Proc. CCP4 Study Weekend (ed. Sawyer, L.) 56-62 (SERC Caresbury Lab., Daresbury, 1993).
44. Furey, W. S. & Swaminathin, S. in Methods in Enzymology: Macromolecular Crystallography Part B Vol. 277 (eds Carter, C. & Sweet, R.) 590-620 (Academic, Orlando, 1997).
45. Cowtan, K. "DM": an automated procedure for phase improvement by density modification. Joint CCP4 ESF-EACBM Newsletter Protein Crystallogr. 31, 34-38 (1994).
46. Collaborative Computational Project Number 4. The CCP4 suite: programs for protein crystallography. Acta Cryst. D 50, 760-776 (1994).
47. Brunger, A. X-PLOR Version 3.0: A System for Crystallography and NMR (Yale Univ. Press, New Haven, 1992).
48. Jones, T. A., Zou, J. Y., Cowan, S. W. & Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Cryst. A 47, 110-119 (1991).